Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | [177]Lu-OncoFAP-23 |
Synonyms | |
Therapy Description |
[177]Lu-OncoFAP-23 is a radioconjugate comprising a FAP ligand linked to Lutetium-177, which delivers radiation to FAP-expressing tumor cells and potentially inhibits tumor growth (PMID: 39266289). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
[177]Lu-OncoFAP-23 | 177Lu-OncoFAP-23 | [177]Lu-OncoFAP-23 is a radioconjugate comprising a FAP ligand linked to Lutetium-177, which delivers radiation to FAP-expressing tumor cells and potentially inhibits tumor growth (PMID: 39266289). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06640413 | Phase I | [177]Lu-OncoFAP-23 + Darleukin [177]Lu-OncoFAP-23 | A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination with L19-IL2 As a Treatment of Metastatic FAP-positive Solid Tumors (Theratri) | Not yet recruiting | ITA | 0 |